Related references
Note: Only part of the references are listed.Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression
Louise Emmett et al.
CLINICAL GENITOURINARY CANCER (2019)
First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Jie Zang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT
Hendrik Rathke et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Mike Sathekge et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Alexander Heinzel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
Thomas W. Barber et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
Burcak Yilmaz et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Bernhard Grubmueller et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Anna Yordanova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Why should we be concerned about a g?
Savvas Frangos et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
Andrei Gafita et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Delayed response after repeated Lu-177-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Kambiz Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
Finn Edler von Eyben et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
K. Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Current status of theranostics in prostate cancer
Irene Virgolini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
Anna Katharina Seitz et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Hendrik Rathke et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy
Christian Uprimny et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
Thomas Langbein et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy
Hojjat Ahmadzadehfar et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
Nusrat J. Begum et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
Zain Khurshid et al.
Oncotarget (2018)
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
Madhav Prasad Yadav et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Shozo Okamoto et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
Justin Ferdinandus et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
Wolfgang P. Fendler et al.
ONCOTARGET (2017)
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
Lorenza Scarpa et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
The impact of repeated cycles of radioligand therapy using [177Lu] Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Anna Yordanova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Braeuer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Hojjat Ahmadzadehfar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer
Matthias M. Heck et al.
JOURNAL OF UROLOGY (2016)
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2016)
Prospective Comparison of F-18-Fluoromethylcholine Versus Ga-68-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
Joshua J. Morigi et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
